Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the potential beneficial effects of a daily supplement of Resveratrol (1000mg/day) on physical ability and on muscle metabolism in patients with verified mitochondrial myopathy and patients with a verified fatty acid oxidation defect of VLCAD and CPTII deficiencies. Investigators hypothesize an improved muscle metabolism, mitochondrial function, fatty acid oxidation and thus improvement of physical ability.


Clinical Trial Description

Study design: double-blind, randomized, placebo-controlled, cross-over study.

To ensure enough participants, and due to the risk of a heterogeneous cohort, a cross-over design is chosen, where participants are their own controls. 10 patients with mitochondrial myopathy and 10 patients with fatty acid oxidation defects will be included. Eligible patients will be randomized using a 1:1 assignment ratio to receive placebo or RSV first. Each treatment will be administered orally twice daily for 8 weeks, followed by a 4 weeks wash-out, and afterwards a new 8-week treatment period.

During the 20-week trial period, subjects will visit the trial site on five occasions, for functional assessments (cycle ergometer testing), blood sampling and questionnaires. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03728777
Study type Interventional
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase N/A
Start date April 9, 2018
Completion date October 1, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT06051448 - Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Phase 1/Phase 2
Completed NCT02909400 - The KHENERGY Study Phase 2
Completed NCT04165239 - The KHENERGYZE Study Phase 2
Recruiting NCT06080568 - Human Mitochondrial Stress-driven Obesity Resistance
Recruiting NCT06080581 - Mitochondrial Dysfunctions Driving Insulin Resistance
Completed NCT02255422 - RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR Phase 2
Completed NCT05012358 - Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine
Recruiting NCT05569122 - Applying pGz in Mitochondrial Disease Phase 1
Completed NCT03888716 - A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease Phase 1
Completed NCT05063721 - MABs Therapy m.3243A>G Mutation Carriers Phase 1
Completed NCT03973203 - Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients N/A
Recruiting NCT05200702 - Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders N/A
Recruiting NCT04086329 - Validation of Oxygen Nanosensor in Mitochondrial Myopathy Phase 1
Completed NCT03513835 - Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies
Completed NCT04538521 - NiaMIT Continuation With Early-stage Mitochondrial Myopathy Patients N/A
Recruiting NCT05554835 - Global Registry and Natural History Study for Mitochondrial Disorders
Completed NCT03432871 - Nicotinamide Riboside and Mitochondrial Biogenesis N/A
Completed NCT02375438 - Nutritional Assessment in Mitochondrial Cytopathy N/A
Recruiting NCT05346627 - Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance. N/A
Recruiting NCT05199740 - mtDNA Mutation Load Analysis in Mesoangioblasts